Search results
1. How should Barrett’s oesophagus be defined and which patients should undergo regular surveillance? 2. Are there clinical features associated with increased cancer risk in Barrett’s oesophagus, which should influence the frequency of endo-scopic surveillance? 3. Are there diagnostic tools that should be uti-lised to screen the ...
8 lut 2023 · This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques.
23 mar 2023 · Furthermore, the correct identification and treatment of dysplastic Barrett’s esophagus is crucial to prevent progression to cancer as well as it is the endoscopic surveillance of treated patients. Herein, we report practice-oriented answers to clinical questions that clinicians should be aware of when approaching patients with Barrett’s esophagus.
Barrett’s esophagus (BE) is characterized by a change of the normal stratified squamous epithelium lining the esophagus to a metaplastic columnar epithelium with goblet cells. The prevalence of BE is estimated to be 1.5% in the general population [1, 2] and as high as 15% in those with gastroesophageal reflux disease (GERD) [3, 4].
22 lis 2011 · In summary, the management of Barrett’s esophagus requires acid suppression and endoscopic assessment. For patients with nondysplastic Barrett’s esophagus, treatment with a PPI may decrease acid exposure and delay the progression to dysplasia.
11 maj 2016 · If dysplasia or neoplasia is confirmed on endoscopy, treatment options include endoscopic mucosal resection or radiofrequency ablation. Barrett’s oesophagus is a premalignant condition where the oesophageal squamous epithelium undergoes columnar change with metaplasia which predisposes to the development of oesophageal adenocarcinoma.
Proton pump inhibitors (PPIs) have the best clinical profile for symptomatic management (Recommendation grade A). Antireflux surgery is not superior to pharmacological acid suppression for the prevention of neoplastic progression of Barrett's oesophagus (Recommendation grade C).
